Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3Myeloid 1

Conditions

Leukemia, Myeloid, Acute 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Blast Crisis 1

Interventions

Specimen Handling 15Biopsy 14fludarabine 12Cytarabine 11Cyclophosphamide 11fludarabine phosphate 10X-Rays 9Whole-Body Irradiation 9venetoclax 8Magnetic Resonance Spectroscopy 8Injections 8asciminib 7Azacitidine 7Nuclear Medicine Department, Hospital 6Mycophenolic Acid 6Busulfan 6decitabine and cedazuridine drug combination 5Tacrolimus 5Phantoms, Imaging 5Melphalan 5Granulocyte Colony-Stimulating Factor 5Filgrastim 5Cyclosporine 5CPX-351 5ruxolitinib 4ivosidenib 4Stem Cell Transplantation 4Peripheral Blood Stem Cell Transplantation 4Idarubicin 4Decitabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
ponatinib × Myeloid × 30 days × Clear all
NCT04188405 2026-06-05

Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia

M.D. Anderson Cancer Center

Phase 2 Completed
20 enrolled
MyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡